Quarterly ResultMay 11, 2026, 04:14 PM
Aura Biosciences Q1 Net Loss $33.7M; Cash Runway into 2H 2028
AI Summary
Aura Biosciences reported a Q1 2026 net loss of $33.7 million, an increase from $27.5 million in Q1 2025, driven by higher R&D and G&A expenses. The company strengthened its balance sheet with an oversubscribed $299 million equity financing, extending its cash runway into the second half of 2028. Key pipeline advancements include the Phase 3 CoMpass trial progressing towards enrollment completion and the appointment of Natalie Holles as the new CEO.
Key Highlights
- Q1 2026 net loss was $33.7 million, up from $27.5 million in Q1 2025.
- Research and development expenses increased to $28.0 million from $23.3 million YoY.
- General and administrative expenses rose to $6.9 million from $5.7 million YoY.
- Completed $299 million equity financing, yielding $280.8 million net proceeds.
- Cash and equivalents, with financing, expected to fund operations into 2H 2028.
- Phase 3 CoMpass trial for early choroidal melanoma advancing, topline data 2H 2027.
- Natalie Holles appointed Chief Executive Officer and President, effective April 30, 2026.
- Early data from Phase 2 choroid metastases and Phase 1b/2 bladder cancer trials expected in 2026.